Research analysts at StockNews.com assumed coverage on shares of Trevena (NASDAQ:TRVN – Get Rating) in a research report issued on Wednesday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.
Separately, HC Wainwright lowered their price target on shares of Trevena to $1.50 in a report on Monday, August 15th.
Trevena Stock Performance
NASDAQ TRVN opened at $3.46 on Wednesday. The company has a quick ratio of 4.51, a current ratio of 4.60 and a debt-to-equity ratio of 0.61. The stock has a market cap of $24.05 million, a price-to-earnings ratio of -0.38 and a beta of 1.86. Trevena has a fifty-two week low of $2.38 and a fifty-two week high of $19.00. The business has a fifty day moving average of $0.87 and a 200-day moving average of $0.50.
Institutional Inflows and Outflows
Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.
- Get a free copy of the StockNews.com research report on Trevena (TRVN)
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Microsoft Shares: Is it Time to Back Up the Truck?
- Three CBD Stocks to Dominate a Budding Industry
- Is the 60/40 Portfolio Mix Still in Vogue?
- Institutional Support for Analog Devices Remains High
Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.